‘Nabota’ having a rough time before entering U.S., is this a rite of passage?

‘Nabota,’ a botulinum toxin product that Daewoong Pharmaceutical has taken as its future growth engine, had suffered not long ago.

The official document(Form 483) published in the U.S. FDA website about the onsite inspection of Nabota Factory become a trigger for the suffering. As interpreting 10 articles in the document as ‘Violation for Manufacturing Process,’ one of the media wrote a press ...